Kevin Lin

Kevin Lin has extensive experience in the field of molecular diagnostics and translational medicine. Kevin is currently the Head of Translational Medicine at REVOLUTION Medicines, a position they have held since January 2023.

Prior to this, Kevin worked at Clovis Oncology, where they held various roles over the years. Kevin started as a Research Scientist in Translational Medicine in August 2010 and worked their way up to Vice President of Molecular Diagnostics and Translational Medicine. During their time at Clovis Oncology, Kevin led various biomarker and diagnostic efforts for the development of rucaparib, a PARP inhibitor. Kevin collaborated with other pharmaceutical companies in biomarker testing for clinical studies and played a significant role in patient identification strategies and the formulation of biomarker plans. Kevin also conducted genomic-based analyses to define molecular modules associated with patient prognosis and therapeutic response.

Overall, Kevin Lin's work experience demonstrates their expertise in molecular diagnostics, translational medicine, and the development of targeted cancer agents.

Kevin Lin began their education journey by earning a Bachelor of Arts degree in Molecular & Cell Biology from the University of California, Berkeley in the years 1996-2000. Kevin then pursued their Ph.D. in Biological Sciences with an emphasis in Bioinformatics, Molecular Biology, Genetics, and Biochemistry from UC Irvine during the period of 2002-2008. Later, Kevin joined the University of California, San Francisco as a Postdoctoral Scholar from 2009-2010, focusing on Cancer Genomics.